LOS ANGELES, April 8, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an article titled "Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells". Data from the trial showed objective responses, including durable, complete regressions, in patients after a single infusion of HPV-TIL.
The trial was designed to determine if the infusion of human papillomavirus tumor-infiltrating lymphocytes (HPV-TIL) could induce regression of advanced HPV-positive cancers.
Of the nine metastatic cervical cancer patients who were enrolled and treated with HPV-TIL, three patients experienced objective tumor responses, two of whom experienced complete, ongoing remissions of 22 and 15 months, respectively. The other patient demonstrated a partial response of three months.
"We are pleased to see the results of this trial, which demonstrate potential efficacy of TIL treatment in metastatic cervical cancer, a notoriously difficult-to-treat cancer in women," said Elma Hawkins, PhD, Lion's president and chief executive officer. "We recently amended our CRADA with the NCI to include technologies based on the HPV-TIL research. With these technologies, we look forward to expanding our clinical programs and developing new treatment options for patients with cervical cancer and other solid tumors."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company's lead product candidate, LN-144, is a ready-to-infuse, autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the uncertainty relating to the efficacy of TIL treatment in metastatic cervical cancer and the Company's ability to file an IND application with the FDA for clinical studies in solid tumor types, such as cervical cancer. Additional risks and uncertainties are described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations The Trout Group Tricia Truehart 646-378-2953 firstname.lastname@example.orgSource:Lion Biotechnologies, Inc.